Dipexium Pharmaceuticals, Inc. just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:
We estimate that the net proceeds we will receive from this offering will be approximately $17.1 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, based on the public offering price of $12.50 per share. If the underwriters exercise their option to purchase additional shares in full, we estimate that the net proceeds to us will be approximate ly $19.7 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We intend to use the net proceeds from this offering for our operations and for other general corporate purposes, including, but not limited to, our internal research and development programs and the development of new programs and general working capital. The occurrence of unforeseen events or changed business conditions, however, could result in the application of the net proceeds from this offering in a manner other than as described in this prospectus supplement. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.
Pending our use of the net proceeds from this offering, we plan to invest the net proceeds in short-term, investment-grade, interest-bearing instruments and U.S. government securities.
Table of Contents
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Regulation FD - Jan. 8, 2018